Role of branched-chain amino acids in liver disease: the evidence for and against
- PMID: 17414498
- DOI: 10.1097/MCO.0b013e3280d646b8
Role of branched-chain amino acids in liver disease: the evidence for and against
Abstract
Purpose of review: There is ample evidence that patients with liver disease have an ongoing energy and protein catabolism. Nutritional management in these patients must receive high priority. The administration of branched-chain amino acids to patients with liver disease has been a controversial subject. This review is an update on the data available from various studies involving branched-chain amino acids supplementation in patients with chronic liver disease and associated complications.
Recent findings: This review summarizes the results of nutritional interventions involving branched-chain amino acids supplementation carried out in different centres around the world. It is interesting to note that no toxic effects of branched-chain amino acids supplementation have been reported in any of these trials.
Summary: Administration of branched-chain amino acids stimulates hepatic protein synthesis in patients with chronic liver disease and this could contribute significantly to improving their nutritional status, and result in a better quality of life. The beneficial role of branched-chain amino acids supplementation in patients with chronic hepatic encephalopathy has been clearly documented in some studies but the exact mechanism of action is still not clear.
Similar articles
-
The role of nutrition in hepatic encephalopathy.Curr Opin Clin Nutr Metab Care. 2008 May;11(3):275-80. doi: 10.1097/MCO.0b013e3282f9e870. Curr Opin Clin Nutr Metab Care. 2008. PMID: 18403924 Review.
-
Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial.Aliment Pharmacol Ther. 2004 Apr 1;19(7):779-88. doi: 10.1111/j.1365-2036.2004.01920.x. Aliment Pharmacol Ther. 2004. PMID: 15043519 Clinical Trial.
-
[Protein catabolism and malnutrition in liver cirrhosis - impact of oral nutritional therapy].Z Gastroenterol. 2010 Jul;48(7):763-70. doi: 10.1055/s-0029-1245388. Epub 2010 Jul 6. Z Gastroenterol. 2010. PMID: 20607635 Review. German.
-
Three targets of branched-chain amino acid supplementation in the treatment of liver disease.Nutrition. 2010 May;26(5):482-90. doi: 10.1016/j.nut.2009.06.027. Epub 2010 Jan 13. Nutrition. 2010. PMID: 20071143 Review.
-
Branched-chain amino acids as pharmacological nutrients in chronic liver disease.Hepatology. 2011 Sep 2;54(3):1063-70. doi: 10.1002/hep.24412. Epub 2011 Jun 23. Hepatology. 2011. PMID: 21563202 Review.
Cited by
-
Acquired hepatocerebral degeneration.J Neurol. 2009 Mar;256(3):320-32. doi: 10.1007/s00415-009-0144-7. Epub 2009 Feb 17. J Neurol. 2009. PMID: 19224314 Review.
-
Current therapies in alleviating liver disorders and cancers with a special focus on the potential of vitamin D.Nutr Metab (Lond). 2018 Feb 9;15:13. doi: 10.1186/s12986-018-0251-5. eCollection 2018. Nutr Metab (Lond). 2018. PMID: 29449867 Free PMC article. Review.
-
Protein tolerance to standard and high protein meals in patients with liver cirrhosis.World J Hepatol. 2017 May 18;9(14):667-676. doi: 10.4254/wjh.v9.i14.667. World J Hepatol. 2017. PMID: 28588751 Free PMC article.
-
Non-invasive urinary metabolomic profiles discriminate biliary atresia from infantile hepatitis syndrome.Metabolomics. 2018 Jun 21;14(7):90. doi: 10.1007/s11306-018-1387-z. Metabolomics. 2018. PMID: 30830373
-
Clinical relevance of sarcopenia in patients with cirrhosis.World J Gastroenterol. 2014 Jul 7;20(25):8061-71. doi: 10.3748/wjg.v20.i25.8061. World J Gastroenterol. 2014. PMID: 25009378 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials